Global Information Inc. would like to present a new market research report, "Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities" by GBI Research.
The overall substance abuse therapeutic market was valued at $8.8 billion in 2011 and is expected to reach $12.7 billion in 2018, at a Compound Annual Growth Rate (CAGR) of 5.3% between 2011 and 2018.
Despite government awareness campaigns, improved treatment access and public health efforts, the substance abuse therapeutic market is not growing at the high rate that might be expected considering the patient populations available. This is because of the difficulties in persuading patients to seek and accept treatment and the problems of compliance and relapse.
Recent years have seen a few discontinuations of products in the substance abuse therapeutics market. One of the major instances of this was Sanofi terminating the development of its smoking cessation product Dianicline due to inadequate differentiation from Chantix (varenicline).
In July 2009, the US Food and Drug Administration (FDA) added a black box label warning on neuropsychiatric effects to the Chantix and Zyban (buprenorphine) labels, which is likely to impede their growth during the forecast period. Further concerns have since been raised over the drugs regarding increasing behavioral changes and suicidal thoughts, and Chantix has more recently raised concerns over claims of increased risk of heart attacks in healthy patients.
The alcohol dependence market was valued at $284m in 2011 and is expected to reach $645m in 2018, growing at a CAGR of 12.4% between 2011 and 2018. Growth shall be driven primarily by a few major products that are expected to be launched during the forecast period, such as Selincro (nalfemene).
Bioties Nalmefene, an opioid antagonist, is expected to launch in early 2013. Nalmefene is a novel treatment option, and its anticipated lack of an alcohol abstinence requirement prior to treatment and as-needed dosing regimen will make the drug an attractive treatment option for patients. However, based on clinical data to date, the drug is not expected to overtake Vivitrols (naltrexone) prescription sales. It faces resistance as it represents a new treatment paradigm, encouraging reduction rather than abstinence.
The market shall also be driven significantly by increasing patient awareness, leading to a higher treatment-seeking rate and better compliance and persistence towards the various therapies.
The pipeline is sparse for the treatment of smoking cessation; the focus of innovation for future products is on patient progression and compliance, and the key players in the market acknowledge the need for this. It is too easy for a patient to stop their treatment in order to regain the positive effects of nicotine which they crave. The main opportunity for growth is therefore in the increase of patient compliance; novel methods of drug delivery such as extended release vaccines are vital for the improvement of efficacy. The leading product in the smoking cessation pipeline is an immunotherapeutic vaccine designed to address these needs.
The late-stage failure of clinical trials for NicVAX (Nicotine Conjugate Vaccine) has come as a blow to Nabi Pharmaceuticals, whose extended release anti-smoking vaccine, was the most promising in the pipeline, and would have driven market growth considerably. There is now considerable doubt over whether NicVAX will reach the market, prolonging the unmet need in this indication for more efficacious extended release treatments.
Increasing concerns over the safety of Pfizers marketed product Chantix, which has the largest market share of any prescription treatment on the market, creates further unmet need in terms of safety. The development of a comparable product with an increased safety profile could damage Chantixs revenues considerably, and drive the market as a whole through increased prescription rate.
Although cocaine abuse is almost five times more prevalent than opioid abuse in the US, opioid abuse therapeutics make up 60% of overall revenues of the substance abuse therapeutic market due to the very high Annual Cost of Treatment (ACT). Pharmacological therapies for cocaine abuse are invariably off-label treatments, which are often out of patent and therefore have a low ACT. There is the opportunity for developing a specific treatment for the indication of cocaine dependence with greater efficacy than the current off-label treatment options. The emergence of such treatments would increase the ACT and drive market revenues.
Global Information Inc.(GII) - specializing in market research provision for the vertical industries, GII offers expert independent recommendations of publications from hundreds of the globe's leading market research firms.